Navigation Links
Max Neeman International Initiates Advisory Committee to Advance and Improve the Conduct of Complex Neurological Trials in India
Date:2/14/2011

RESEARCH TRIANGLE PARK, N.C., Feb. 14, 2011 /PRNewswire/ -- India's premier CRO, Max Neeman, participated in the 59th annual Neurological Society of India & Congress of Neurological Surgeons (NEUROCON) held in Jaipur, India this past December.  The event was a convergence of leading neuroscientists, neurosurgeons, neurologists, physicians, surgeons, biotechnologists and researchers from across the globe to discuss advances made in the area of Neurology & Neurosurgery.

(Logo: http://photos.prnewswire.com/prnh/20110105/CL25129LOGO)

Max Neeman brought together USA and India based renowned group of Neuro and Spinal surgeons from prestigious hospitals across India and USA to form an advisory committee.

The Advisory Committee is to develop strategies for clinical research across newer therapies for central nervous system disorders.  Regulatory challenges and technical issues along with associated strategies of conducting the clinical trials of newer therapies in India were planned.

Max Neeman has conducted approximately 10% surgical intervention trials to date of over 230 trials awarded.  As part of the Max India Group, Max Neeman collaborates with 'Max Healthcare's' top physicians and neurosurgeons across India including Neurosciences departments, and one dedicated Neurological Institute, as part of the [8] hospital group; Max Healthcare.

About Max Neeman International

Max Neeman International is one of the leading and largest CROs in India and the clinical research arm of healthcare conglomerate, Max India.  Our specialty is that we offer services for the successful conduct of Phase I-IV clinical and device trials for small and mid-sized international and national Pharmaceutical, Biotechnology, Medical Device and Nutraceutical companies in compliance with ICH GCP standards. Operational since 2001, Max Neeman is an ISO 9001:2008 certified CRO for Monitoring, Site Management and Data Management Services. The company has 6 regional offices and 175 sites across 31 cities. Contact Donald Swankie, Vice President USA via email to donald.swankie@neeman-medical.com or call +1.919.424.3345.  www.neeman-medical.com

About Max Healthcare

Also part of the Max India group, Max Healthcare is part of a leading chain of hospitals in India.  Its state of the art infrastructure, top-notch physicians, and most advanced technologies makes it one of the best hospitals in the country. www.maxhealthcare.in


'/>"/>
SOURCE Max Neeman International
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Indias Favorable and Progressive Regulatory Environment Causes Accelerated Growth of Max Neeman Internationals Regulatory Services
2. Max Neeman International Signs Agreement for Data Management/EDC of Large Phase IV Trials from Multiple Sites
3. Max Neeman International to Open Phase I/IIa Unit
4. International Isotopes Inc. Announces a Shareholder Conference Call for February 7, 2011
5. Bacterin International Holdings Secures $5,000,000 Credit Facility with Bridge Bank
6. 4th International Conference on Electrophoretic Deposition
7. Verenium Announces Favorable Outcome of Capital Ventures International Lawsuit
8. Cellular Dynamics International to Present at 29th Annual JPMorgan Healthcare Conference
9. Halt Medical Presents Strong Results of International Fibroid Studies at National Institutes of Health Global Congress
10. Web of international collaboration boosts worldwide nanotechnology research
11. ViroPharma Incorporated and Idis Partner to Facilitate International Access to Certain ViroPharma Therapeutics Through Named Patient Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... MILPITAS, Calif. , Feb. 17, 2017 /PRNewswire/ ... posters detailing data on its oral peptide drug ... Congress of the European Crohn,s and Colitis ... in Barcelona, Spain from ... The posters detail preclinical data on Protagonist drug ...
(Date:2/16/2017)... and GREENWICH, Conn. ... private investment firm focused on venture growth investments ... promotion of Josh Richardson , M.D. to ... investments in biotechnology companies.  He is a board ... important roles in Longitude,s investments in Aimmune Therapeutics, ...
(Date:2/16/2017)... Feb. 16, 2017   Capricor Therapeutics, Inc. ... biotechnology company developing first-in-class biological therapies for cardiac ... has elected to terminate its license agreement with ... agonists, including Cenderitide. "Our decision to ... we prioritize our efforts to advance our core ...
(Date:2/16/2017)... Feb. 16, 2017  Dermata Therapeutics, LLC, a ... treat a variety of dermatological diseases, today announced ... financing and entered into a $5 million credit ... to use the capital for general corporate purposes ... in the treatment of serious diseases treated by ...
Breaking Biology Technology:
(Date:2/9/2017)... , Feb. 9, 2017 The biomass boiler ... of the biomass boiler market globally in terms of ... biomass boilers. The market for biomass boilers has been ... end-user, application, and country/region. The market based on feedstock ... forest residues, biogas & energy crops, urban residues, and ...
(Date:2/8/2017)... Report Highlights The global biosurgery market should ... 2016 at a compound annual growth rate (CAGR) of ... An overview of the global market for biosurgery. - ... and 2016, and projections of compound annual growth rates ... the basis of product type, source, application, and region. ...
(Date:2/3/2017)... , Feb. 3, 2017  Texas Biomedical Research Institute announced ... Larry Schlesinger as the Institute,s new President and ... effective May 31, 2017. He is currently the Chair of ... the Center for Microbial Interface Biology at Ohio State University. ... the new President and CEO of Texas Biomed," said Dr. ...
Breaking Biology News(10 mins):